厄达非替尼

厄达非替尼（CAS 1346242-81-6）的独立参考数据，整理自公开化学数据库。

各数据库的登记标识

计算分子描述符

在册的理化数值

在册的记载用途

Erdafitinib is a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor that is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. The selection of patients for the treatment of locally advanced or metastaticErdafitinib is an oral small molecule inhibitor of fibroblast growth factor (FGF) receptors 1 to 4 that is used in the therapy of locally advanced, unresectable or metastatic urothelial carcinoma. Erdafitinib has been associated with a high rate of serum enzyme elevations during therapy, but has not been linked to cases of clinically apparent acute liver injury.

同义词与商品名

Erdafitinib; 1346242-81-6; Balversa; 890E37NHMV; DTXSID001027936; N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-N-propan-2-ylethane-1,2-diamine; erdafitinibum; N'-(3,5-dimethoxyphenyl)-N'-(3-(1-methylpyrazol-4-yl)quinoxalin-6-yl)-N-propan-2-ylethane-1,2-diamine; RefChem:57639; DTXCID201513503; JNJ-42756493; N1-(3,5-dimethoxyphenyl)-N2-isopropyl-N1-(3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl)ethane-1,2-diamine; MFCD28502040; Balversa (TN); ERDAFITINIB [WHO-DD]; JNJ 42756493

GHS 危害分类

Reported hazard statements	H302 (100%), H317 (100%), H318 (100%), H335 (20%), H361 (80%), H372 (80%), H373 (20%), H413 (80%)

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

H317 (100%): May cause an allergic skin reaction [Warning Sensitization, Skin]

公开数据库对它的描述

Erdafitinib · CAS 1346242-81-6 · C25H30N6O2. UNII 890E37NHMV. Solubility: <1 mg/mL.

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。